From Cchek to CAR-T, ITUS Is On Track

We got the chance to speak with Dr. Amit Kumar, the CEO of ITUS Corp. this last week. Having heard little about the progress...

Moffitt Cancer Center and ITUS Corporation Announce Scheduling of Pre-IND Meeting with the FDA

Tailwinds' Take: these meetings are important steps towards approval of an IND and are not at all perfunctory as they involve significant time and...

Why Tiny ITUS’s CAR-T Therapy Could Be A Big Deal In Cancer Treatment

For the past few years modifying T-Cells to express Chimeric Antigen Receptors, a practice known as “CAR-T”,  has been the hottest space in cancer...

Moffitt Cancer Center and ITUS Corporation Request Meeting with FDA Regarding Ovarian Cancer CAR-T...

Tailwinds Take: with an aggressive timeline, ITUS' CAR-T therapy could be in humans in less than a year from today. If successful, it would...

ITUS Corporation Releases Results for Cchek™ Breast Cancer Study

Tailwinds' Take: More excellent, albeit early, data out of ITUS. Their Cchek platform is showing amazing efficacy in multiple cancers and has the potential...

ITUS Corporation Announces Second Commercial Focus for Cchek™ will be Breast Cancer

Tailwinds' Take: it appears that ITUS is seeing clinical success in multiple cancer types for them to be selecting a second indication at this...

Yes, ITUS’ Data Was Really That Good!

The recent press release issued by ITUS regarding its CAR-T program was spectacular news for the company. However, based on some questions I have received,...

ITUS: Accelerates Advance of Solid Tumor CAR-T Program

This morning ITUS Corp. announced that they have moved forward the development timeline of their CAR-T therapy being developed in conjunction with the Moffitt...

ITUS Accelerates Schedule for its CAR T Therapy and Provides Update

Tailwinds' Take: very positive development in the most exciting space in healthcare. SAN JOSE, Calif., June 26, 2018 /PRNewswire/ -- ITUS Corporation (NASDAQ: ITUS) today provided...

ITUS Followup Notes

I had a follow-up call with Dr. Kumar, CEO of ITUS, today. Basically, I was looking to understand more about the benign versus cancerous...

ITUS Corporation Announces First Commercial Focus for Cchek™ will be Prostate Cancer

Tailwinds' Take: ITUS has a potentially game-changing diagnostic here. Dr. Kumar's comments about benign studies are quite foreshadowing. We can expect to hear more...

No Doldrums For ITUS, Instead a Busy Summer Awaits

Last month Grail Inc. raised $300 million in a Series C equity financing. This brings their total raised to around $1.5B over the last...

Digging Deeper Into ITUS: an Interview with CEO, Dr. Amit Kumar

In a big week for ITUS, the Company announced outstanding results on a study undertaken with Memorial Sloan Kettering Cancer Center (MSK) and Serametrix,...

ITUS and Serametrix Announce Results of a Blinded Prostate Cancer Study

Tailwinds' Take: amazing endorsement of ITUS' Cchek technology by the premier cancer center. Cchek appears to have the potential to completely disrupt cancer diagnostics. SAN...

ITUS Announces Issuance of Second Key Cancer Detection Technology Patent

Tailwinds' Take: as ITUS continues to show clinical success on Cchek, protecting the IP will be critical to maintaining the incredible TAM. ITUS' patent...

ITUS to Present Data from Early Cancer Detection Study Utilizing Artificial Intelligence at the...

SAN JOSE, Calif., March 16, 2018 /PRNewswire/ -- ITUS Corporation (NASDAQ: ITUS), today announced that it will present the latest data from its ongoing early...

ITUS will Present Data at the American Association of Cancer Research (AACR) Annual Meeting

SAN JOSE, Calif., March 12, 2018 /PRNewswire/ -- ITUS Corporation (NASDAQ: ITUS), today announced that it will present data from its ongoing study utilizing Cchek™,...

ITUS: Implications of the Serametrix Partnership

On March 5th, ITUS announced an alliance with Serametrix Corporation in which the power of Cchek™ would be paired with Serametrix’s substantial expertise in...

ITUS Corporation Forms Alliance with Serametrix Corporation

Tailwinds' Take: Serametrix has a substantial volume of MDSC testing results, both historical and ongoing, on which Cchek can be evaluated. My guess is...

ITUS, CEO Update Interview

Last week, ITUS reported data on a study of their novel cancer diagnostic, C-Chek. I had the opportunity to check in and discuss this...